article · Scientia Pharmaceutica
An observational study of 105 age- and weight-matched outpatients examined the impact of type 2 diabetes mellitus-induced hyperglycaemia on individuals with non-alcoholic fatty liver disease who present with normal liver function tests. Patients were evaluated across two cohorts, comparing those with non-alcoholic fatty liver disease alone against those with concurrent diabetes-related hyperglycaemia. Blood measurements included serum levels of triglycerides, low-density lipoprotein, oxidative stress indicators such as hydrogen peroxide and malondialdehyde, and inflammatory cytokines comprising tumour necrosis factor-alpha and interleukin-6. The results demonstrated that hyperglycaemia caused significant deterioration in lipid profiles alongside substantial increases in both oxidative stress markers and pro-inflammatory mediators. Plasma glucose concentrations correlated positively with each of these biological markers. These clinical findings reveal that hyperglycaemia exacerbates disease pathogenicity even when liver enzyme tests show normal readings.
Non-alcoholic fatty liver disease can advance silently when standard liver function tests appear normal. Demonstrating that high blood sugar intensifies oxidative stress, inflammation and lipid disruption in these patients clarifies how diabetes accelerates liver damage. This evidence underlines the necessity of diligent glucose tracking to identify heightened disease risks before severe complications such as steatohepatitis, cirrhosis or liver cancer can develop.
The study represents early-stage clinical observational research that points toward future medical applications. The findings suggest opportunities for pharmaceutical developers to investigate adding antioxidant and anti-inflammatory therapies to treatment programmes for diabetic patients with non-alcoholic fatty liver disease. It also indicates potential utility for healthcare providers and diagnostic services in designing combined monitoring protocols, though formal clinical trials would be required before any therapeutic or commercial adoption.
AI-generated from the published abstract. Always read the original work before citing.
Type 2 diabetes mellitus is associated with dyslipdemia, insulin resistance and non alcoholic fatty liver disease. The purpose of the current study was to assess whether type 2 diabetes mellitus-induced hyperglycemia has an effect on the lipid profile and release of oxidative stress markers and inflammatory mediators in patients with non alcoholic fatty liver disease and normal liver function tests which may in turn lead to enhancing the pathogenicity of this liver disease. For this purpose, one hundred and five outpatients, matched in age and weight, were classified into two groups: the first group consisted of patients with non alcoholic fatty liver disease and the second group consisted of patients with non alcoholic fatty liver disease in conjunction with hyperglycemia due to the presence of type 2 diabetes mellitus. In all patients, lipid profile, oxidative stress, and inflammatory mediators were assessed by measuring serum concentrations of triglycerides, low density lipoprotein, hydrogen preroxide, malondialdehyde, tumor necrosis factor-alpha and interleukin-6, respectively. In the studied population, it was found that the presence of type 2 diabetes mellitus-induced hyperglycemia significantly impaired lipid profile, and significantly enhanced the formation of hydrogen preroxide and malondialdehyde as well as significantly increased the release of tumor necrosis factor-alpha and interleukin-6 in the second group of patients. In addition, plasma glucose level showed significant positive correlation with hydrogen peroxide, malondialdehyde, tumor necrosis factor-alpha and interleukin-6. From the previous results, it was concluded that the presence of type 2 diabetes mellitus-induced hyperglycemia results in significant increase in lipid profile, oxidative stress markers and inflammatory mediators in patients with non alcoholic fatty liver disease and normal liver function tests. For this reason, further research studies may be essential to evaluate the benefit of adding suitable antioxidant and anti-inflammatory drugs to the treatment regimen for this group of patients. In addition, regular monitoring of blood glucose levels and liver function tests should be advised to this category of patients to reduce liver fat deposition and avoid the development of non alcoholic steatohepatitis, cirrhosis or liver cancer and their related complications.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3797/scipharm.1104-21
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
